Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

Publisher: La Merie Publishing
Pages: 162
Format: PDF
Product Line:
LMP Full Report
Product Code: LMFR0005
Release Date: October of 2011

2,400.00 €
(Discount: 20.00%)
1,920.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

Product description

The report “Coagulation Factors 2011 – who does meet the market needs?
A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis” provides a description, evaluation and assessment of the recombinant coagulation factor R&D pipelines as of October 2011. The authors analyze and assess the target pipeline for each of the coagulation factors for haemophilia and work out the target profiles of development projects. A market research study was conducted to challenge industry’s target profiles and evaluate the sensitivity for pricing.

The report is built upon primary and secondary search for information and use of a proprietary database and news portal. A market survey was conducted among haematologists from haemophilia care centers. In house analysts with experience in biopharmaceutical R&D and business development authored the report and analysed and assessed the findings.

Global sales of the five major recombinant products of coagulation factors VIII, IX and VIIa in 2010 were US$ 6.2 bln (with $ conversion rate October 19, 2010). The first Marketing Authorization Application for a novel recombinant coagulation factor has been submitted in the European Union and further novel wild-type and long-acting recombinant coagulation factors VIII, IX and VII are in advanced clinical stages with potential regulatory approvals within the next 2 to 4 years. Given the progress of the pipeline, a concentration process of players has started. First clinical data are available and will guide further definition of R&D in this field.

Scope of the report

  • R&D pipeline overview;
  • profiles of most promising coagulation factors in the pipeline
  • pipeline analysis for each coagulation factor
  • evaluation and assessment of protein engineering and drug delivery technologies
  • overview and analysis of marketed coagulation factors;
  • market research study with haematologists from haemophilia care centers
  • corporate product portfolios and R&D pipelines;
  • benchmark of competitors regarding achievement of product target profiles

Benefits from the report

  • Understand your position in a highly competitive environment
  • Learn what haematologists think about your product target profiles
  • Understand the market needs
  • Know pricing sensitivities for your haemophilia products
  • Learn from your competitors
  • Challenge your strategy with a view from outside the organization

Download sample pages: Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

Table of Contents

0 Abbreviations

1 Executive Summary

2 Overview

3 Coagulation Factor Markets
3.1 Recombinant Factor VIIIa Market
3.2 Recombinant Factor IXa Market
3.3 Recombinant Factor VIIa Market
3.4 Total Market Size of Recombinant Coagulation Factors for Hemophilia
3.5 Recombinant Thrombin Market
3.6 Total Market Sizes and Market Shares of Rec. Coagulation Factors
3.7 Plasma-Derived Coagulation Factors

4 Pipeline Changes since September 2010
4.1 Alnylam Pharmaceuticals
4.2 Amsterdam Molecular Therapeutics
4.3 Baxter
4.4. Bayer Healthcare Pharmaceuticals
4.5 Biogen Idec
4.6 Catalyst Biosciences
4.7 CSL
4.8 Green Cross
4.9 Grifols (Talecris Biotherapeutics)
4.10 Ipsen & Inspiration Biopharmaceuticals
4.11 LFB (GTC Biotherapeutics)
4.12 Novo Nordisk
4.13 Octapharma
4.15 Pharmstandard
4.16 Pfizer (Wyeth)
4.17 ProFibrix
4.18 Prolor Biotech
4.19 PTC Therapeutics
4.20 ReGenRx Biosciences

5 Target Pipeline Analysis
5.1 Factor VIII
5.2 Factor IX
5.3 Factor VII
5.4 Alternative Procoagulants & Adjuncts
5.5 Factor XIII
5.6 von Willebrand Factor (vWF)
5.7 Fibrinogen & Thrombin

6 Market Research: Survey on Novel Coagulation Factors
6.1 Methodology
6.2 Results: Profile of Participant, Center and Usage of Factors
6.3 Results:Valuation of Characteristics of New Hemophilia Products
6.4 Results: Decisive Characterstics to Switch to New Hemophilia Products
6.5 Results: Price Sensitivity of Characteristics of New Products
6.6 Results: Factors Influencing Decision to Switch to New Products
6.7 Results: Role of Plasma-Derived Coagulation Factors
6.8 Assessment of Survey Results

7 Corporate Benchmark Analysis
7.1 Time to Market
7.2 Immunogenicity
7.3 Administration Frequency
7.4 Pricing: Me Toos and Biosimilars
7.5 Non-Intravenous Administration
7.6 Safety Features of Drug Substance and Drug Product
7.7 Novel Procoagulants and Adjuvants

8 References

9 Tables in the Text

Table 1 Sales of Advate/Recombinate
Table 2 Sales of Kogenate (FS)
Table 3 Sales of Helixate
Table 4 Sales of Refacto (AF) / Xyntha
Table 5 2010 Sales of Recombinant Factor VIIIa Products
Table 6 Growth of the Recombinant Factor VIIIa Market
Table 7 Sales of BeneFIX
Table 8 Sales of NovoSeven
Table 9 Total Market Size of Rec Coagulation Factors in Hemophilia
Table 10 CAGR of the Rec Coagulation Factor Market in Hemophilia
Table 11 Sales of Recothrom
Table 12 Market Shares of Individual Rec Coagulation Factors
Table 13 Sales of Thrombin-JMI Product Family
Table 14 Sales of Koate DVI
Table 15 Sales of Grifols’ pdFVIII Products
Table 16 2010 Sales of Selected Systemic pd Coagulation Factors
Table 17 2010 Sales of Selected Topical pd Coagulation Factors
Table 18 Baxter’s Coagulation Factors Pipeline
Table 19 BAX 326: Clinical Studies
Table 20 BAX 111: Clinical Studies
Table 21 Baxter’s Strategic Goals in Hemophilia
Table 22 Bayer’s Coagulation Factors Pipeline
Table 23 BAY 81-8973: Clinical Studies
Table 24 Bayer’s Strategic Goals in Hemophilia
Table 25 Biogen Idec’s Coagulation Factor Pipeline
Table 26 rFIXFc Clinical Studies
Table 27 rFVIIFc Clinical Studies
Table 28 Biogen Idec’s Strategic Goals in Hemophilia
Table 29 Catalyst Biosciences’ Coagulation Factor Pipeline
Table 30 Catalyst Biosciences Strategic Goals in Hemophilia
Table 31 CSL’s Recombinant Coagulation Factor Pipeline
Table 32 CSL’s Strategic Goals in Hemophilia
Table 33 Green Cross’ Pipeline of Coagulation Factors in Hemophilia
Table 34 Green Cross’s Strategic Goals in Hemophilia
Table 35 Grifols’ Pipeline of Rec. Coagulation Factors in Hemophilia
Table 36 Grifols’ Strategic Goals in Hemophilia
Table 37 Ipsen and Inspiration’s Coagulation Factor Pipeline
Table 38 Ipsen and Inspiration’s Strategic Goals in Hemophilia
Table 39 LFB’s Pipeline of Recombinant Coagulation Factors
Table 40 Novo Nordisk’s Pipeline of Coagulation Factors
Table 41 Turoctocog alfa: Clinical Studies
Table 42 NN7128: Clinical Studies
Table 43 Novo Nordisk’s Strategic Goals in Hemophilia
Table 44 Octapharma’s Recombinant Coagulation Factor Pipeline
Table 45 Human-cl rFVIII: Clinical Studies
Table 46 Octapharma’s Strategic Goals in Hemophilia
Table 47 Pharmstandard’s Coagulation Factor Pipeline
Table 48 Pfizer’s Coagulation Factor Pipeline
Table 49 Pfizer’s Strategic Goals in Hemophilia
Table 50 ProFibrix’ Pipeline of Coagulation Factors
Table 51 ProFibrix’ Strategic Goals with Coagulation Factors.
Table 52 PROLOR Biotech’s Coagulation Factor Pipeline
Table 53 Product Characteristics of improved rhu F. VIII products
Table 54 Overview of rFVIII Pipeline
Table 55 Features of Novel Wild-Type rFVIII Molecules in R&D
Table 56 Pharmacokinetics of Long-Acting rFVIII Molecules
Table 57 Features of Novel Long-Acting rFVIII Molecules in R&D
Table 58 Overview of rFIX Pipeline
Table 59 Pharmacokinetics of Long-Acting rFIX Molecules
Table 60 Features of Novel Long-Acting rFIX Molecules in R&D
Table 61 Overview of rFVII Pipeline
Table 62 Features of Novel WT or Short-Acting rFVII Molecules
Table 63 Pharmacokinetics of Long-Acting rFVII Molecules
Table 64 Features of Novel Long-Acting rFVII Molecules in R&D
Table 65 Rating of characteristics of future hemophilia producs
Table 66 Summary of Ranking of Product Characteristics
Table 67 Benchmarking for Novel F.VIII Molecules
Table 68 Benchmarking for Novel F. IX Molecules
Table 69 Benchmarking for Novel F. VII Molecules
Table 70 Benchmarking for Novel Procoagulants & Adjuvants
Table 71 Potential First Approvals in EU or USA

10 Figures in the Text
Figure 1 Territory of residency of participants
Figure 2 Number of hemophilia patients in centers of participants
Figure 3 Qualification, function & responsibility of participants
Figure 4 Usage of rec and pd coagulation factors in centers
Figure 5 Valuation of characteristics of future hemophilia producs
Figure 6 Prioritization of characteristics of future hemophilia products
Figure 7 Single characteristics making to switch to new product
Figure 8 Combination of characteristics inducing a switch decision
Figure 9 Sensitivity for pricing of new products – single characteristic
Figure 10 Influence of territory on sensitivity for pricing
Figure 11 Sensitivity for pricing of new products – combined features
Figure 12 Sensitivity for pricing of a “Me Too” / “Biosimilar” product
Figure 13 Attributes for selection of new hemophilia products
Figure 14 Requested data for claim of “less inhibitor formation”
Figure 15 Impact of Aledort meta-analysis on prescribing praxis
Figure 16 Impact of Aledort meta-analysis on long-acting


Companies mentioned in the report

Alnylam Pharmaceuticals
Amsterdam Molecular Therapeutics
Archemix
Baxter
Bayer HealthCare Pharmaceuticals
Biogen Idec
Biotest
Bristol-Myers Squibb (Zymogenetics)
Catalyst Biosciences
CSL
Fresenius Kabi
Green Cross
Grifols (Talecris Biotherapeutics)
Ipsen & Inspiration Biopharmaceuticals
Johnson & Johnson (Ethicon; OMRIX Biopharmaceuticals)
Kedrion
LFB (GTC Biotherapeutics)
Medgenics
Nektar Therapeutics
Novo Nordisk
Nycomed
Octapharma
Pfizer (Wyeth; King Pharmaceuticals)
Pharming
ProFibrix
PROLOR Biotech
Proteomtech
ReGenRx Biosciences
Scil Proteins
Swedish Orphan Biovitrum
Xenetic Biosciences (Lipoxen)



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top